Improving the drug development process by reducing the impact of adverse events:the case of cataracts considered

Smith, Andrew F, Klotz, Alexander and Wormstone, I. Michael (2016) Improving the drug development process by reducing the impact of adverse events:the case of cataracts considered. Drug Discovery Today, 21 (3). pp. 510-516. ISSN 1359-6446

[img]
Preview
PDF (Smith et al Final) - Submitted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (147kB) | Preview

Abstract

Cataract was used as a model for the prevalence and economic impact of adverse events during the drug development process. Meta-analysis revealed a reported prevalence of cataract at 12.0% (1.0–43.3%), 3.8% (2.4–12.5%), 1.0% (0.0–8.1%), 1.7% (0.0–34.8%) and 3.8% (2.3–5.7%) of compounds in preclinical, Phase I, II, III and IV clinical trials, respectively. Utilising a human-based in vitro screening assay to predict cataractogenic potential in human could allow better selection of novel compounds at early-stage drug development. This could significantly reduce costs and ultimately increase the probability of a drug obtaining FDA approval for a clinical application.

Item Type: Article
Faculty \ School: Faculty of Science > School of Biological Sciences
Depositing User: Pure Connector
Date Deposited: 22 Mar 2016 09:23
Last Modified: 24 Jun 2020 23:57
URI: https://ueaeprints.uea.ac.uk/id/eprint/57740
DOI: 10.1016/j.drudis.2016.01.001

Actions (login required)

View Item View Item